(+)-MCL-740 | 1533458-73-9

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 英文名称: (+)-MCL-740
• CAS: 1533458-73-9
• 化学式: C₂₇H₃₄N₂O
• 分子量: 402.58
• InChiKey: PPVICXFDCXSVFQ-STXQHDJLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.91
• 重原子数：
  30.0
• 可旋转键数：
  5.0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  24.5
• 氢给体数：
  1.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  (+)-MCL-740 在 盐酸 作用下， 以 甲醇 、 乙醚 为溶剂， 生成 (+)-MCL-740
  参考文献：
  名称：

  Preliminary Pharmacological Evaluation of Enantiomeric Morphinans

  摘要：

  A series of levo- and dextromorphinan pairs have been synthesized and evaluated for their affinities to the mu, kappa, and delta opioid receptors, the N-methyl-D-aspartate (NMDA) channel, and sigma 1 and 2 receptors. It was found that levo isomers tended to have higher affinities at the opioid receptors and moderate to high affinities to the NMDA and sigma receptors, while dextro isomers tended to have lower affinities to the opioid receptors but comparatively higher affinities to the NMDA and sigma receptors. This series of compounds have interesting and complex pharmacological profiles, and merit further investigation as potential therapies for drug abuse treatment.

  DOI：

  10.1021/cn400205z
• 作为产物：
  描述：

  (+)-3-羟基吗啡烷 在 lithium aluminium tetrahydride 、 [(2-di-cyclohexylphosphino-3,6-dimethoxy-2′,4′,6′-triisopropyl-1,1′-biphenyl)-2-(2′-amino-1,1′-biphenyl)]palladium(II) methanesulfonate 、 potassium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 叔丁醇 为溶剂， 反应 1.5h， 生成 (+)-MCL-740
  参考文献：
  名称：

  Preliminary Pharmacological Evaluation of Enantiomeric Morphinans

  摘要：

  A series of levo- and dextromorphinan pairs have been synthesized and evaluated for their affinities to the mu, kappa, and delta opioid receptors, the N-methyl-D-aspartate (NMDA) channel, and sigma 1 and 2 receptors. It was found that levo isomers tended to have higher affinities at the opioid receptors and moderate to high affinities to the NMDA and sigma receptors, while dextro isomers tended to have lower affinities to the opioid receptors but comparatively higher affinities to the NMDA and sigma receptors. This series of compounds have interesting and complex pharmacological profiles, and merit further investigation as potential therapies for drug abuse treatment.

  DOI：

  10.1021/cn400205z